CD106 (VCAM-1), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-CD106 (VCAM-1), Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD106 (VCAM-1), Human |
| Clone | REAL273 |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | n/a |
| Format | phycoerythrin (PE) conjugate |
| Size | 200 µL |
| Concentration | n/a |
| Applications | MICS (MACSima Imaging Cyclic Staining), Immunohistochemistry, Immunofluorescence |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | CD106 (VCAM-1) Antibody, anti-human, PE, REAdye_lease™. Clone REAL273 is an antibody fragment derived from the full CD106 (VCAM-1) antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity. | Clone REAL273 recognizes the CD106 (VCAM-1) antigen, a 110 kDa single chain type I glycoprotein also known as vascular cell adhesion protein 1 (VCAM-1) or INCAM-100. CD106 is expressed on inflamed vascular endothelium, as well as on macrophage-like and dendritic cell types in both normal and inflamed tissue. Upregulation of CD106 in endothelial cells by inflammatory stimuli and cytokines occurs as a result of increased gene transcription. Primarily, CD106 is an endothelial ligand for very late antigen-4 (VLA-4) or integrin α-4/β-7 and mediates both adhesion and signal transduction. The interactions play a pathophysiologic role in leukocyte adhesion, transmigration, and co-stimulation of T cell proliferation. | For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675). | |
| Immunogen | n/a |
| Other Names | VCAM1, INCAM-100 |
| Gene, Accession # | n/a |
| Catalog # | 130-127-042 |
| Price | $470 |
| Order / More Info | CD106 (VCAM-1), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Osborn, L. et al. (1992) Activated endothelium binds lymphocytes through a novel binding site in the alternately spliced domain of vascular cell adhesion molecule-1. J. Exp. Med. 176 (1): 99-107. | Barreiro, O. et al. (2002) Dynamic interaction of VCAM-1 and ICAM-1 with moesin and ezrin in a novel endothelial docking structure for adherent leukocytes. J. Cell Biol. 157 (7): 1233-1245. | Johnson, L. A. et al. (2008) Cell traffic and the lymphatic endothelium. Ann. N. Y. Acad. Sci. 1131: 119-133. | Schlesinger, M. et al. (2015) Vascular cell adhesion molecule-1 (VCAM-1)--an increasing insight into its role in tumorigenicity and metastasis. Int. J. Cancer 136 (11): 2504-2514. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies